GlassScriptPhysician profile
Taylor Catherine Taraski
NPI 1205355773
$1,019.13
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $633 · 2023: $151 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $148.93 | 2022-2024 | |
| Amgen INC. | $144.56 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Merck Sharp & Dohme LLC | $85.07 | 2022-2024 | Keytruda |
| Tersera Therapeutics LLC | $69.99 | 2022-2024 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $65.89 | 2022-2023 | Imbruvica |
| Daiichi Sankyo INC. | $59.88 | 2022-2024 | Injectafer |
| Seagen INC. | $54.98 | 2022-2023 | Padcev |
| Genzyme Corporation | $46.71 | 2022-2024 | |
| Genentech USA, INC. | $41.10 | 2023 | Kadcyla, Phesgo, Perjeta |
| Astrazeneca Pharmaceuticals LP | $35.47 | 2022-2024 | |
| Incyte Corporation | $29.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.85 | 2022 | |
| Eisai INC. | $26.56 | 2022 | |
| Genmab U.S., INC. | $24.06 | 2023 | Epkinly |
| Macrogenics, INC. | $23.49 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.18 | 2024 | Iclusig |
| Pharmacosmos Therapeutics INC. | $21.56 | 2024 | Monoferric |
| Puma Biotechnology, INC. | $17.15 | 2022 | |
| G1 Therapeutics, INC. | $16.38 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.92 | 2022 | |
| Astellas Pharma US INC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Taraski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.